Confluent Medical will leverage both NDC and Interface technologies to expand its relationships with customers in the endovascular, neurovascular, transcatheter heart valve, peripheral vascular, orthopedic and other markets, the company said.

“The acquisition of Interface reflects our commitment to investing in material science technologies that enable us to best serve the medical device community. The NDC-Interface combination is an excellent strategic fit and we are excited to leverage the key talent and technical expertise of the combined companies to provide world class, differentiated products to our customers,” CEO Dean Schauer said in a press release.

“It has long been a goal of NDC to apply its manufacturing, quality systems and technical expertise beyond Nitinol, broadening the manufacturing and outsourcing solutions we can offer to customers. The exceptional technical strength of Interface with polymers, catheters and balloons provides the perfect opportunity to accomplish just that,” CTO Tom Duerig said in a prepared statement.